---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T23:22:02.393978'
end_time: '2026-01-11T23:29:35.927092'
duration_seconds: 453.53
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: NEUROD1
  gene_symbol: NEUROD1
  uniprot_accession: Q13562
  protein_description: 'RecName: Full=Neurogenic differentiation factor 1; Short=NeuroD;
    Short=NeuroD1; AltName: Full=Class A basic helix-loop-helix protein 3; Short=bHLHa3;'
  gene_info: Name=NEUROD1; Synonyms=BHLHA3, NEUROD;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: bHLH_dom. (IPR011598); bHLH_transcription_factors. (IPR050359);
    HLH_DNA-bd_sf. (IPR036638); NeuroD_DUF. (IPR022575); TF_bHLH_NeuroD. (IPR016637)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 10
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13562
- **Protein Description:** RecName: Full=Neurogenic differentiation factor 1; Short=NeuroD; Short=NeuroD1; AltName: Full=Class A basic helix-loop-helix protein 3; Short=bHLHa3;
- **Gene Information:** Name=NEUROD1; Synonyms=BHLHA3, NEUROD;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** bHLH_dom. (IPR011598); bHLH_transcription_factors. (IPR050359); HLH_DNA-bd_sf. (IPR036638); NeuroD_DUF. (IPR022575); TF_bHLH_NeuroD. (IPR016637)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "NEUROD1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'NEUROD1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **NEUROD1** (gene ID: NEUROD1, UniProt: Q13562) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q13562
- **Protein Description:** RecName: Full=Neurogenic differentiation factor 1; Short=NeuroD; Short=NeuroD1; AltName: Full=Class A basic helix-loop-helix protein 3; Short=bHLHa3;
- **Gene Information:** Name=NEUROD1; Synonyms=BHLHA3, NEUROD;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** bHLH_dom. (IPR011598); bHLH_transcription_factors. (IPR050359); HLH_DNA-bd_sf. (IPR036638); NeuroD_DUF. (IPR022575); TF_bHLH_NeuroD. (IPR016637)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "NEUROD1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'NEUROD1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **NEUROD1** (gene ID: NEUROD1, UniProt: Q13562) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview
- Verified identity: NEUROD1 (Neurogenic differentiation factor 1; NeuroD/NeuroD1; BETA2) is a human Group A basic helix-loop-helix (bHLH) transcription factor consistent with UniProt Q13562, with a basic DNA-binding region recognizing E-boxes and an HLH dimerization domain; roles are conserved across neural and endocrine lineages (reviewed 2024). (pavlinkova2024neurod1transcriptionaland pages 2-3, pavlinkova2024neurod1transcriptionaland pages 1-2)
- Collected and synthesized recent evidence (2024–2025) on: molecular function and chromatin engagement; developmental programs (neuronal, pancreatic endocrine); disease links (MODY6; cancer subtypes); and translational applications. (pavlinkova2024neurod1transcriptionaland pages 3-5, pavlinkova2024neurod1transcriptionaland pages 6-7, takumida2025integrativeepigenomeand pages 4-4, takumida2025integrativeepigenomeand pages 4-7, yang2025theexpressionorder pages 8-11, pavlinkova2024neurod1transcriptionaland pages 5-6)

Gene/protein identity, domains, and core concepts
- Identity and family: NEUROD1 is a Group A bHLH transcription factor expressed in the nervous system and endocrine pancreas. It was originally identified as a proneural factor capable of converting non-neural ectoderm to neurons, consistent with a master regulator of neuronal differentiation. (Pavlinkova & Smolik, 2024, Frontiers in Cell and Developmental Biology, Jul 2024; https://doi.org/10.3389/fcell.2024.1435546) (pavlinkova2024neurod1transcriptionaland pages 1-2, pavlinkova2024neurod1transcriptionaland pages 9-10)
- Domains and DNA binding: The basic region mediates sequence-specific binding to E-box motifs (canonical CANNTG), while the HLH region mediates homo- and heterodimerization with other bHLH partners, shaping binding selectivity and transcriptional outcomes. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 2-3)
- Dimerization partners and co-factors: Reported interactions include heterodimerization with class I bHLH E proteins (e.g., TCF12/E2-2) and cooperation with lineage TFs (e.g., FOXG1 in neurogenesis), consistent with context-dependent combinatorial regulation. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 6-7)
- Subcellular localization: As a transcription factor, NEUROD1 functions in the nucleus where it binds regulatory DNA and interacts with chromatin remodelers (e.g., SWI/SNF ATPase BRG1), consistent with nuclear localization of bHLH TFs. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 2-3)

Molecular function and mechanisms (current understanding)
- Core function: NEUROD1 binds enhancers/promoters of neuronal and endocrine genes to activate lineage programs; direct neural targets include developmental TFs and neuronal genes such as Pou3f2, Insm1, Nhlh1, Atoh1, Neurod4, and Nhlh2. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 2-3)
- Chromatin engagement and potential pioneer activity: Multiple studies summarized in 2024 show NEUROD1 can engage previously inaccessible chromatin, be associated with loss of repressive H3K27me3 and gain of H3K27ac at target loci, and increase chromatin accessibility, consistent with pioneer-like behavior in some contexts. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 6-7, pavlinkova2024neurod1transcriptionaland pages 8-9)
- Temporal hierarchy with NGN3 in pancreas: New in 2025, a Science Advances study in mouse pancreas shows NEUROD1 typically acts as a conventional factor downstream of NGN3 during endocrine differentiation; however, in the absence of NGN3, forced NEUROD1 can partially assume pioneering roles, highlighting context-dependent pioneer capacity shaped by expression order. (Yang et al., 2025, Science Advances, Mar 2025; https://doi.org/10.1126/sciadv.adt4770) (yang2025theexpressionorder pages 8-11)

Biological processes and localization of activity
- Neuronal development: NEUROD1 is essential for survival, differentiation, maturation, and integration of neurons in multiple regions (e.g., hippocampus, inner ear), with deletion causing severe neurodevelopmental phenotypes in mice. NEUROD1 directly binds neural developmental regulatory elements and can override pluripotency to initiate neuronal programs. Nuclear activity is supported by its direct DNA and chromatin interactions. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 3-5, pavlinkova2024neurod1transcriptionaland pages 2-3, pavlinkova2024neurod1transcriptionaland pages 9-10)
- Pancreatic endocrine differentiation: NEUROD1 is detectable by E9.5 in mouse pancreas, maintained in mature β cells, and is required for early α/β cell differentiation, β-cell functional maturation, and insulin responsiveness; Neurod1 loss leads to perinatal lethal hyperglycemia, massive β-cell/insulin loss, and reduced expression of key β-cell TFs (MAFA, NKX6-1, PDX1, INSM1, NKX2-2, ISL1, PAX6, RFX6). (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 3-5)
- Enteroendocrine lineage: NEUROD1 is a canonical regulator of endocrine cell programs; while human EEC-specific dynamics were not directly extracted here, the pancreas and neuroendocrine evidence support its role in endocrine fate acquisition and maturation at nuclear regulatory elements. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 8-9, pavlinkova2024neurod1transcriptionaland pages 3-5)

Recent developments and latest research (2024–2025)
- Context-dependent pioneer capacity in pancreas: The 2025 study (Yang et al.) quantitatively demonstrates that NeuroD1 knockout reduces α and β cell proportions and downregulates endocrine TFs (e.g., Insm1, Isl1, Nkx2-2, Rfx6, Pax4), while chromatin accessibility changes are modest unless NeuroD1 is expressed before/without NGN3, when it can open sites and partially drive endocrine trajectories. (Science Advances, 2025; https://doi.org/10.1126/sciadv.adt4770) (yang2025theexpressionorder pages 8-11)
- SCLC transcriptional programs: A 2025 Oncogene study maps NEUROD1 motif-specific binding in small cell lung cancer, showing that NEUROD1 sustains super-enhancer–associated target genes; knockout downregulates SE genes significantly (SE vs others p = 4.37×10−7) and reduces expression of NEUROD2, CHRNA3/CHRNB4, NTNG2, NHLH2. This defines a NEUROD1-high SCLC subtype and shows partial independence from ASCL1. (Oncogene, Jul 2025; https://doi.org/10.1038/s41388-025-03481-2) (takumida2025integrativeepigenomeand pages 4-4, takumida2025integrativeepigenomeand pages 4-7)

Target genes and pathways
- Neural lineage targets: Direct binding near Pou3f2, Insm1, Nhlh1, Atoh1, Neurod4, Nhlh2 supports NEUROD1’s role in establishing neuronal identity programs. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 2-3)
- Endocrine network integration: NEUROD1 supports expression of key β-cell TFs and hormones; loss reduces MAFA, NKX6-1, PDX1, INSM1, NKX2-2, ISL1, PAX6, RFX6, concordant with β-cell failure and diabetes phenotypes. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 3-5)
- Cancer-associated programs: In SCLC, NEUROD1 directly or indirectly sustains NE lineage genes and cholinergic receptor subunits (CHRNA3/CHRNB4) and cooperates with super-enhancer architecture, marking an autonomous regulatory axis distinct from ASCL1 in many genes. (Oncogene, 2025; URL above) (takumida2025integrativeepigenomeand pages 4-4, takumida2025integrativeepigenomeand pages 4-7)

Disease associations and clinical genetics
- MODY6 (NEUROD1-MODY): Human NEUROD1 mutations cause a rare MODY subtype with heterogeneous phenotypes from mild hyperglycemia to severe diabetes; a 2024 family study reported a novel nonsense mutation c.747C>G associated with MODY6, expanding the variant spectrum. (Journal of Diabetes, Sep 2024; https://doi.org/10.1111/1753-0407.13607) (pavlinkova2024neurod1transcriptionaland pages 5-6)
- NEUROD1 and diabetes mechanisms: The experimental mouse data align with human MODY6, where reduced endocrine TF networks and insulin expression underlie β-cell dysfunction, consistent with NEUROD1’s nuclear regulatory role in β cells. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 3-5)
- Cancer subtypes: NEUROD1 defines a molecular subtype of SCLC (NEUROD1-high) with specific target gene programs and reliance on super-enhancer–driven networks, informing biomarker and therapeutic-stratification strategies. (Oncogene, 2025; URL above) (takumida2025integrativeepigenomeand pages 4-4, takumida2025integrativeepigenomeand pages 4-7)

Current applications and real-world implementations
- Cellular reprogramming: NEUROD1 is widely used in neuronal reprogramming protocols in vitro and in vivo, including viral delivery to glia or non-neuronal cells to induce neuronal programs; numerous studies demonstrate robust neurogenic activity, while endocrine conversion typically requires additional factors (e.g., PDX1, INSM1, MafA). These applications leverage NEUROD1’s ability to rewire transcriptional and chromatin states in the nucleus. (Pavlinkova & Smolik, 2024; URL above) (pavlinkova2024neurod1transcriptionaland pages 5-6, pavlinkova2024neurod1transcriptionaland pages 6-7)
- Gene therapy and neuroregeneration: Reviews emphasize in vivo delivery (AAV/LV) using NEUROD1 for neuroregeneration, though lineage tracing and delivery specificity remain critical translational considerations. (Summarized in 2024 review) (pavlinkova2024neurod1transcriptionaland pages 8-9)

Expert perspectives and analysis
- Mechanistic positioning: The convergence of 2024–2025 data supports a model in which NEUROD1 is a sequence-specific nuclear transcription factor that can act as a pioneer factor in a context-dependent manner. In pancreas, NGN3 generally pioneers endocrine chromatin, with NEUROD1 consolidating and executing endocrine programs; yet, NEUROD1 can pioneer when expressed first or alone. In neural and cancer contexts, NEUROD1 sustains super-enhancer–linked transcriptional hubs and coordinates lineage-specific modules. (Pavlinkova & Smolik, 2024; Yang et al., 2025; Takumida et al., 2025) (pavlinkova2024neurod1transcriptionaland pages 6-7, yang2025theexpressionorder pages 8-11, takumida2025integrativeepigenomeand pages 4-7)
- Clinical translation: For MODY6, precision genetic diagnosis informs management and family counseling; the expanding variant spectrum (e.g., 2024 c.747C>G nonsense) underscores the need for functional annotation of variants. In oncology, defining NEUROD1-high SCLC by genomic and epigenomic profiling may refine patient stratification and reveal vulnerabilities in super-enhancer–dependent transcription. (Li et al., 2024; Takumida et al., 2025) (pavlinkova2024neurod1transcriptionaland pages 5-6, takumida2025integrativeepigenomeand pages 4-4)

Relevant statistics and data points (recent)
- SCLC NEUROD1 functional genomics: NEUROD1 knockout in Lu134A cells caused 226 transcripts upregulated and 235 downregulated; super-enhancer–associated genes were preferentially downregulated (SE vs others p = 4.37×10−7), including NEUROD2, CHRNA3/CHRNB4, NTNG2, and NHLH2. (Oncogene, 2025; https://doi.org/10.1038/s41388-025-03481-2) (takumida2025integrativeepigenomeand pages 4-4, takumida2025integrativeepigenomeand pages 4-7)
- Pancreatic differentiation: NeuroD1 deletion reduced α and β cell proportions and downregulated endocrine TFs (e.g., Insm1, Isl1, Nkx2-2, Rfx6, Pax4) while upregulating progenitor genes; chromatin accessibility effects were subtle unless NEUROD1 acted before NGN3. (Science Advances, 2025; https://doi.org/10.1126/sciadv.adt4770) (yang2025theexpressionorder pages 8-11)
- MODY6 genetics: A novel NEUROD1 nonsense variant (c.747C>G) was identified in a Chinese pedigree with MODY6 in 2024, reinforcing NEUROD1’s causal role in monogenic diabetes. (Journal of Diabetes, 2024; https://doi.org/10.1111/1753-0407.13607) (pavlinkova2024neurod1transcriptionaland pages 5-6)

Key definitions and concise summary of roles
- NEUROD1 (Q13562) is a nuclear bHLH transcription factor that dimerizes to bind E-boxes, regulates chromatin and transcription of neuronal and endocrine gene programs, and can pioneer chromatin in specific contexts. Its developmental functions are essential for neuronal maturation and pancreatic endocrine differentiation; clinically, NEUROD1 mutations cause MODY6, and NEUROD1 defines a molecular subtype of SCLC with super-enhancer–dependent transcriptional programs. Its reprogramming capacity is broadly leveraged in neuroregeneration and lineage conversion strategies. (Pavlinkova & Smolik, 2024; Yang et al., 2025; Takumida et al., 2025) (pavlinkova2024neurod1transcriptionaland pages 2-3, pavlinkova2024neurod1transcriptionaland pages 3-5, yang2025theexpressionorder pages 8-11, takumida2025integrativeepigenomeand pages 4-4)

URLs and publication dates for cited sources
- Pavlinkova & Smolik, 2024 (Frontiers in Cell and Developmental Biology), Jul 2024: https://doi.org/10.3389/fcell.2024.1435546 (review) (pavlinkova2024neurod1transcriptionaland pages 1-2, pavlinkova2024neurod1transcriptionaland pages 2-3, pavlinkova2024neurod1transcriptionaland pages 3-5, pavlinkova2024neurod1transcriptionaland pages 6-7, pavlinkova2024neurod1transcriptionaland pages 8-9)
- Yang et al., 2025 (Science Advances), Mar 2025: https://doi.org/10.1126/sciadv.adt4770 (yang2025theexpressionorder pages 8-11)
- Takumida et al., 2025 (Oncogene), Jul 2025: https://doi.org/10.1038/s41388-025-03481-2 (takumida2025integrativeepigenomeand pages 4-4, takumida2025integrativeepigenomeand pages 4-7)
- Li et al., 2024 (Journal of Diabetes), Sep 2024: https://doi.org/10.1111/1753-0407.13607 (pavlinkova2024neurod1transcriptionaland pages 5-6)

Limitations
- Some desired specifics (e.g., experimentally mapped nuclear localization motifs for human NEUROD1; detailed human enteroendocrine cell dynamics) were not directly available in the extracted evidence set here; claims were therefore limited to sources and contexts with explicit evidence. (pavlinkova2024neurod1transcriptionaland pages 1-2, pavlinkova2024neurod1transcriptionaland pages 2-3)

References

1. (pavlinkova2024neurod1transcriptionaland pages 2-3): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

2. (pavlinkova2024neurod1transcriptionaland pages 1-2): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

3. (pavlinkova2024neurod1transcriptionaland pages 3-5): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

4. (pavlinkova2024neurod1transcriptionaland pages 6-7): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

5. (takumida2025integrativeepigenomeand pages 4-4): Hiroshi Takumida, Akira Saito, Yugo Okabe, Yasuhiro Terasaki, Yu Mikami, Hidenori Tanaka, Masami Suzuki, Yu Hamaguchi, Chao Zeng, Michiaki Hamada, Hiroshi I. Suzuki, Hidenori Kage, and Masafumi Horie. Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ascl1 and neurod1 in small cell lung cancer. Oncogene, Jul 2025. URL: https://doi.org/10.1038/s41388-025-03481-2, doi:10.1038/s41388-025-03481-2. This article has 3 citations and is from a domain leading peer-reviewed journal.

6. (takumida2025integrativeepigenomeand pages 4-7): Hiroshi Takumida, Akira Saito, Yugo Okabe, Yasuhiro Terasaki, Yu Mikami, Hidenori Tanaka, Masami Suzuki, Yu Hamaguchi, Chao Zeng, Michiaki Hamada, Hiroshi I. Suzuki, Hidenori Kage, and Masafumi Horie. Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ascl1 and neurod1 in small cell lung cancer. Oncogene, Jul 2025. URL: https://doi.org/10.1038/s41388-025-03481-2, doi:10.1038/s41388-025-03481-2. This article has 3 citations and is from a domain leading peer-reviewed journal.

7. (yang2025theexpressionorder pages 8-11): Liu Yang, Xin-Xin Yu, Xin Wang, Chen-Tao Jin, and Cheng-Ran Xu. The expression order determines the pioneer functions of ngn3 and neurod1 in pancreatic endocrine differentiation. Science Advances, Mar 2025. URL: https://doi.org/10.1126/sciadv.adt4770, doi:10.1126/sciadv.adt4770. This article has 3 citations and is from a highest quality peer-reviewed journal.

8. (pavlinkova2024neurod1transcriptionaland pages 5-6): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

9. (pavlinkova2024neurod1transcriptionaland pages 9-10): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

10. (pavlinkova2024neurod1transcriptionaland pages 8-9): Gabriela Pavlinkova and Ondrej Smolik. Neurod1: transcriptional and epigenetic regulator of human and mouse neuronal and endocrine cell lineage programs. Frontiers in Cell and Developmental Biology, Jul 2024. URL: https://doi.org/10.3389/fcell.2024.1435546, doi:10.3389/fcell.2024.1435546. This article has 15 citations and is from a poor quality or predatory journal.

## Citations

1. yang2025theexpressionorder pages 8-11
2. takumida2025integrativeepigenomeand pages 4-4
3. takumida2025integrativeepigenomeand pages 4-7
4. https://doi.org/10.3389/fcell.2024.1435546
5. https://doi.org/10.1126/sciadv.adt4770
6. https://doi.org/10.1038/s41388-025-03481-2
7. https://doi.org/10.1111/1753-0407.13607
8. https://doi.org/10.3389/fcell.2024.1435546,
9. https://doi.org/10.1038/s41388-025-03481-2,
10. https://doi.org/10.1126/sciadv.adt4770,